Health care costs in a randomized trial of antimicrobial duration among cystic fibrosis patients with pulmonary exacerbations.

MLA

Gold, Laura S., et al. “Health Care Costs in a Randomized Trial of Antimicrobial Duration among Cystic Fibrosis Patients with Pulmonary Exacerbations.” Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society, vol. 21, no. 4, July 2022, pp. 594–99. EBSCOhost, https://doi.org/10.1016/j.jcf.2022.03.001.

APA

Gold, L. S., Hansen, R. N., Patrick, D. L., Tabah, A., Heltshe, S. L., Flume, P. A., Goss, C. H., West, N. E., Sanders, D. B., VanDevanter, D. R., & Kessler, L. (2022). Health care costs in a randomized trial of antimicrobial duration among cystic fibrosis patients with pulmonary exacerbations. Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society, 21(4), 594–599. https://doi.org/10.1016/j.jcf.2022.03.001

Chicago

Gold, Laura S, Ryan N Hansen, Donald L Patrick, Ashley Tabah, Sonya L Heltshe, Patrick A Flume, Christopher H Goss, et al. 2022. “Health Care Costs in a Randomized Trial of Antimicrobial Duration among Cystic Fibrosis Patients with Pulmonary Exacerbations.” Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society 21 (4): 594–99. doi:10.1016/j.jcf.2022.03.001.